Safety of Locally Delivered Allogeneic Mesenchymal Stromal Cells
Safety of Locally Delivered Allogeneic Mesenchymal Stromal Cells for Promoting Corneal Repair
Sponsor: United States Department of Defense
A PHASE1 clinical study on Cornea and Corneal Defect, this trial is completed. The trial is conducted by United States Department of Defense and has accumulated 12 data snapshots since 2021. Longitudinal tracking of this trial contributes to a broader understanding of treatment development timelines.
Status Flow
Change History
12 versions recorded-
Jan 2025 — Present [monthly]
Completed PHASE1
Status: Recruiting → Completed
-
Sep 2024 — Jan 2025 [monthly]
Recruiting PHASE1
-
Jul 2024 — Sep 2024 [monthly]
Recruiting PHASE1
-
Mar 2024 — Jul 2024 [monthly]
Recruiting PHASE1
Status: Active Not Recruiting → Recruiting
-
Jan 2024 — Mar 2024 [monthly]
Active Not Recruiting PHASE1
Status: Recruiting → Active Not Recruiting
▶ Show 7 earlier versions
-
Jun 2023 — Jan 2024 [monthly]
Recruiting PHASE1
-
May 2022 — Jun 2023 [monthly]
Recruiting PHASE1
-
Sep 2021 — May 2022 [monthly]
Recruiting PHASE1
-
Apr 2021 — Sep 2021 [monthly]
Recruiting PHASE1
-
Feb 2021 — Apr 2021 [monthly]
Recruiting PHASE1
-
Jan 2021 — Feb 2021 [monthly]
Recruiting PHASE1
-
Dec 2020 — Jan 2021 [monthly]
Recruiting PHASE1
First recorded
Eligibility Summary
No eligibility information available.
Contact Information
- United States Department of Defense
- University of Illinois at Chicago
For direct contact, visit the study record on ClinicalTrials.gov .